INDUSTRIAL IMPACT

Inventors of biolayer interferometry technology launch a next gen platform and novel biosensors

Gator Bio | September 15, 2021

Gator Bio, Inc. announced today the launch of the GatorPlus, a next generation biolayer interferometry (BLI) instrument and two new biosensor products, Gator™ Flex SA Kit and Gator™ AAVX probe. The GatorPlus adds to the currently available GatorPrime instrument; and the new Gator™ Flex SA Kit and Gator™ AAVX probe expand the off the shelf biosensor portfolio to 14 products for the North America market. Gator Bio also offers on demand custom biosensors for specific application needs. GatorPlus is a bench-top instrument for real-time label-free analysis of molecular interactions and quantitation in 96-well or 384-well microplates. The instrument offers longer walk-away time and more automation compared to GatorPrime, the first Gator instrument launched in March 2019.    

Based on Gator Bio's proprietary technology, the Gator™ Flex SA Kit is the industry's first ever reactivable streptavidin biosensor for BLI. It can be reactivated and reused more than 20 times without performance degradation, enabling significant cost saving for Gator system customers. The Gator™ AAVX probe quantitates many serotypes of AAVs automatically in minutes, greatly simplifying AAV developers' workflow. The results obtained from the Gator™ AAVX probes correlate tightly to the gold standard method.

Gator Bio was founded by Dr. Hong Tan and Mr. Robert Zuk, the pioneers of biolayer interferometry. The company has been focused on development and commercialization of the next generation BLI that greatly enhances the performance and cost effectiveness of this simple yet powerful analytical technology. In addition to the newly introduced Gator™ Flex SA Kit and Gator™ AAVX probes, Gator Bio offers a wide range of products, including the highly sensitive SMAP biosensor and the regenerable mouse Fc capture biosensor. The Gator systems and associated biosensors provide convenient kinetic analysis and concentration determination for the development of antibody and protein therapeutics.

 

"We saw problems and shortcomings with the original BLI technology, so we decided to come back to close the gaps with new ways to realize BLI. Our objective is to enable the most effective and efficient BLI systems for scientists".   

  - Dr. Hong Tan, CEO of Gator Bio. 


About Gator Bio,Inc.
Gator Bio is a life sciences company providing bioanalytical systems to accelerate the development of therapeutics and diagnostics. Gator Bio along with its sister company ET Healthcare are part of Access Medical Systems. The Gator instruments and biosensors enable real-time analysis of biomolecular interactions providing information on affinity, kinetics, concentration and epitope binning, etc. Most importantly, Gator Bio's analytical capabilities enable better and faster characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance, and cost. The company is headquartered in Palo Alto, California with facilities in Shanghai and Suzhou, China.

Spotlight

Signaling molecules enable fast and maintained communication between brain cells and are essential for brain function. The diverse roles and actions of these molecules as neurotransmitters and neuromodulators have been the subject of years of research. This infographic details The classic neurotransmitters and neuromodulators of the brain, their molecular structures and their roles in brain cell communication.

Spotlight

Signaling molecules enable fast and maintained communication between brain cells and are essential for brain function. The diverse roles and actions of these molecules as neurotransmitters and neuromodulators have been the subject of years of research. This infographic details The classic neurotransmitters and neuromodulators of the brain, their molecular structures and their roles in brain cell communication.

Related News

Sestina Bio Launches Engineering Biology to Create Revolutionary Products

Sestina Bio | October 17, 2020

Sestina Bio, a new company creating a platform for automated synthetic biology, today announced that it has launched with seed funding from Foresite Capital, General Inception and OMX Ventures. The funds will be used to further the development of its digital cellular engineering and phenotyping platforms and support initial product development. The firm is the first company to launch from incubator Foresite Labs. Practitioners of synthetic biology aim to engineer novel living organisms -- usually yeast and bacteria -- that produce new materials, fine and bulk chemicals, and pharmaceuticals, or which act as sensors that report on their environment. By combining new instruments for single cell genome editing, tools for single cell phenotyping, and closed-loop, machine learning-driven design and control of experiments, Sestina is developing the next generation of the automated synthetic biology toolkit. Sestina will harness these tools to rapidly and deterministically engineer new biological capabilities and produce novel products across several verticals.

Read More

CELL AND GENE THERAPY

Vizgen Releases Commercial MERSCOPE Platform

Vizgen | August 31, 2021

Vizgen, the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced shipment of the first commercial MERSCOPETM Platforms, marking the successful start of their limited summer release program. These first platforms are being purchased by leading research institutes including the Salk Institute, the University of California, Irvine, and the Beth Israel Deaconess Medical Center. Vizgen will continue shipping a limited number of commercial instruments for the next several months before releasing MERSCOPE to the U.S. market at large in late 2021. MERSCOPE is the first commercially available high-plex single-cell spatial genomics platform, and the only platform for MERFISH technology. Developed in the laboratory of Dr. Xiaowei Zhuang, a Howard Hughes Medical Institute Investigator, and David B. Arnold, Jr. Professor of Science at Harvard University, MERFISH provides the highest detection efficiency available for spatially profiling gene expression across whole tissues and resolving individual transcripts with nanometer-scale resolution through combinatorial labeling, sequential imaging, and error-robust barcoding. “This is a revolutionary time for the field of genomics. Researchers across the country are now able to access the spatial dimension to answer new kinds of scientific questions and make significant biological discoveries,” said Terry Lo, President and CEO of Vizgen. “Profiling the expression of hundreds of genes, in hundreds of thousands of cells, for hundreds of millions of transcripts all while retaining the spatial information within the tissue architecture has never been done before. What was previously unimaginable, MERSCOPE now makes routine.” About Vizgen Vizgen is dedicated to pioneering the next generation of genomics, providing tools that demonstrate the possibilities of in situ single cell spatial genomics, setting the standard for the spatial genomics field. These tools are enabling researchers to gain new insight into the biological systems that govern human health and disease with spatial context. The company's MERSCOPETM platform enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and unrivaled detection efficiency at subcellular resolution. MERSCOPE provides transformative insight into a wide range of tissue-scale basic research and translational medicine in oncology, immunology, neuroscience, infectious disease, developmental biology, cell and gene therapy, and is an essential tool for accelerating drug discovery and development.

Read More

INDUSTRY OUTLOOK

Expanding Diagnostics Business: SCHOTT Signs Agreement to Acquire Applied Microarrays Inc.

Applied Microarrays Inc. | September 30, 2021

SCHOTT MINIFAB, a subsidiary of SCHOTT that develops and manufactures microfluidic devices for point-of-care and life sciences consumables, has had a long-standing close customer relationship with Applied Microarrays Inc. (AMI). Together, they develop biotech substrates for diagnostics applications. The expertise of AMI will further strengthen SCHOTT’s ability to offer a single-source contract manufacturing solution. The deal is expected to close in early October. Through this acquisition, SCHOTT MINIFAB significantly expands its biosensor printing capabilities. This is of particular importance as demand is growing for the manufacturing of point-of-care microarray consumables, especially in applications such as infectious disease detection. “We pride ourselves on being an end-to-end partner for the global diagnostics industry. Our expansive offering allows us to provide an integrated single-source collection of value-intensive services and products. With the added bioscience knowledge of AMI, we become an even stronger partner, enhancing our capability in surface modification, functionalization and deposition for both glass and polymer products.” - Greg Wolters, Head of SCHOTT MINIFAB. AMI will soon be moving to a larger facility in the Phoenix, Arizona area. Its new location will greatly increase SCHOTT’s manufacturing footprint in the United States to serve its global customer base. Pioneering – responsibly – together These attributes characterize SCHOTT as a manufacturer of high-tech materials based on specialty glass. Founder Otto Schott is considered its inventor and became the pioneer of an entire industry. Always opening up new markets and applications with a pioneering spirit and passion – this is what has driven the #glasslovers at SCHOTT for more than 130 years. Represented in 34 countries, the company is a highly skilled partner for high-tech industries: Healthcare, Home Appliances & Living, Consumer Electronics, Semiconductors & Datacom, Optics, Industry & Energy, Automotive, Astronomy & Aerospace. In the fiscal year 2020, its 16,500 employees generated sales of 2.24 billion euros. With the best teams, supported by the best digital tools, the group intends to continue to grow. SCHOTT AG is owned by the Carl Zeiss Foundation, one of the oldest foundations in Germany. It uses the Group's dividends to promote science. As a foundation company, SCHOTT has anchored responsibility for employees, society and the environment deeply in its DNA. The goal is to become a climate-neutral company by 2030. About Applied Microarrays (AMI) AMI is a company headquartered in Tempe, AZ, which designs, optimizes and manufactures DNA and protein biosensors, and other microarrays on glass, plastic and semiconductors. AMI operates under ISO 9001 and ISO 13485 certification. Since acquiring GE Healthcare’s microarray business in 2007, AMI has evolved to become a full service provider for RUO and Dx devices.

Read More